Preserving the Ocular Surface: Practice Pearls – Part V

1.00 CME
1.00 CME WITH ABO Continuing Certification
$0 FEE
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Preserving the Ocular Surface: Practice Pearls – Part V


Provider Statement

This continuing medical education activity is provided by Vindico Medical Education

Support Statement

This activity is supported by independent medical education grants from Alcon Vision, LLC; Kala Pharmaceuticals, Inc.; Oyster Point Pharma, Inc.; Regeneron Pharmaceuticals, Inc.; and Sun Pharmaceutical Industries, Inc.

Activity Description

Early identification and prompt management of patients with ocular surface disease (OSD) can lessen disease severity and help achieve earlier resolution. However, OSD continues to be challenging to differentially diagnose, and therefore, it is frequently undertreated. The continued assessment and refinement of diagnostic and management algorithms, along with advances in ocular imaging and therapeutic modalities, have the potential to enhance both visual acuity outcomes and quality of life in patients with OSD. Recent and emerging additions to the therapeutic armamentarium provide expanded treatment options for patients with dry eye, meibomian gland dysfunction, and other types of ocular surface disease. In this educational activity, expert clinicians review diagnostic modalities and therapeutic strategies for the management of OSD, offering practical guidance through the presentation of challenging clinical cases. Faculty will also differentiate current and emerging therapeutic strategies for their ability to optimize therapy, improve patient outcomes, and maintain a healthy ocular surface.

Target Audience

The intended audience for this activity is comprehensive ophthalmologists and other health care professionals involved in the management of patients with ocular surface disease.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Evaluate new methods and modalities for the diagnosis, assessment, and monitoring of ocular surface disease.
  • Review the treatment of ocular surface disease in specific patient populations, including those with comorbidities.
  • Differentiate current and emerging therapeutic strategies for their ability to optimize therapy, improve patient outcomes, and aid in prevention of ocular surface disease.

Activity Chair

Elizabeth Yeu, MD
Assistant Professor of Ophthalmology
Eastern Virginia Medical School
Surgeon, Cornea, Cataract, External Disease and Refractive Surgery
Virginia Eye Consultants
Medical Director, CVP Mid-Atlantic
Norfolk, VA


Eric D. Donnenfeld, MD
Ophthalmic Consultants of Long Island
Clinical Professor of Ophthalmology
New York University
Trustee, Dartmouth Medical School
New York, NY

Francis S. Mah, MD
Director, Cornea Service
Co-Director, Refractive Surgery
Scripps Clinic
La Jolla, CA

Lisa M. Nijm, MD, JD
CEO, Women in Ophthalmology
Founder and Medical Director, Warrenville EyeCare and LASIK
Assistant Clinical Professor of Ophthalmology, University of Illinois Eye and Ear Infirmary
Chicago, IL


Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning and Self-Assessment requirements for the American Board of Ophthalmology’s Continuing Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting credit.

Upon successful completion, learners who opt-in by providing their ABO ID and DOB (MM/DD) will earn credits equivalent to the amount of CME credits claimed for the activity.

This enduring material is approved for 1 year from the date of original release, July 16, 2021, to July 15, 2022.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 4 out of 6 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.


In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears below.  

Activity Chair and Faculty report the following relationship(s)

Eric D. Donnenfeld, MD
Consulting Fee: Alcon, Allegro, Allergan, Avellino Labs, Bausch + Lomb, BlephEx, BVI, CorneaGen, Covalent, CRST, Dompé , ELT Sight, EyePoint, Foresight, Glaukos, Ivantis, J&J Vision, Kala, Katena, LacriPen, LensGen, Mati Pharmaceuticals, MDbackline, Merck, Mimetogen, Nanowafer, NovaBay, Novaliq, Novartis, Ocular Innovations, OcuHub, Oculis, Odyssey, Omega Ophthalmics, Omeros, Oyster Point Therapeutics, Pfizer, PogoTec, PRN, Regener-Eyes, ReTear, RPS, Shire, Strathspey Crown, Sun, Surface, Tarsus, TearLab, TearScience, Thea, TLC Laser Centers, Veracity, Versant Ventures, Visionary Ventures, Visus, Zeiss
Ownership Interest: Avedro, CorneaGen, Covalent, ELT Sight, EyePoint, Glaukos, Ivantis, LacriPen, LensGen, Mati Pharmaceuticals, MDbackline, Mimetogen, NovaBay, OcuHub, Ocular Innovations, Oculis, Orasis, PogoTec, Regener-Eyes, ReTear, RPS, Strathspey Crown, Surface, Tarsus, TearLab, Veracity, Versant Ventures, Visionary Ventures, Visus

Francis S. Mah, MD
Consulting Fee: Aerie, Alcon, Allergan, Aperta, Avellino, Azura, Bausch + Lomb, BlephEx, Dompé, Eyenovia, EyePoint, Eyevance, Glaukos, Ivantis, iView, J&J Vision, Kala, Mallinckrodt, Nevakar, Novartis, NuSight, Ocular Therapeutix, Okogen, Omeros, Oyster Point, PolyActiva, Sight Sciences, Sun, Thea
Ownership Interest: Avellino, iView, Ocular Science, Okogen, Sydnexis

Lisa M. Nijm, MD, JD
Consulting Fee: Akorn, Alcon, Allergan (Abbott), Azura, Bausch + Lomb, Bruder, CooperVision, EyePoint, J&J Vision, Kala, Novartis, Ocular Therapeutix, Omeros, Sun, Zeiss
Speakers Bureau: Kala, Omeros, Sun
Contracted Research: Ocular Therapeutix
Medical Advisory Board: LacriScience

Elizabeth Yeu, MD
Consulting Fee: Alcon, Allergan, Avedro, Bausch + Lomb, Beaver Visitec, Bio-Tissue, BlephEx, Bruder, CorneaGen, Dompé, Expert Opinion, EyePoint, Guidepoint, J&J Vision, Kala, LENSAR, Melt, Merck, Mynosys, Novartis, Ocular Science, Ocular Therapeutix, OCuSOFT, Omeros, Oyster Point, Science Based Health, Shire, Surface, Tarsus, TearLab, Thea, Topcon, Visus, Zeiss
Contracted Research: Alcon, Bio-Tissue, Ocular Science, TearLab, Topcon
Ownership Interest: BlephEx, CorneaGen, Melt, Ocular Science, Oyster Point, Tarsus

Reviewer reports the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at